XENE Stock Xenon Pharmaceuticals (XENE, $39.83) price exceeded its 50-day Moving Average on November 15, 2024

GET DAILY SIGNALS

Get AI intraday signals

XENE - Xenon Pharmaceuticals

Moving Avg. signal

View

Odds of DOWN Trend

Price: $39.83

Daily change: -$1.92 (-4.6%)

Daily volume: 654K

Capitalization: $3B

Industry: Biotechnology

XENE's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for XENE moved out of overbought territory on November 08, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 15, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on XENE as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XENE turned negative on November 13, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

XENE moved below its 50-day moving average on November 15, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XENE broke above its upper Bollinger Band on November 07, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for XENE crossed bullishly above the 50-day moving average on October 10, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 214 cases where XENE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.807) is normal, around the industry mean (14.849). P/E Ratio (0.000) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). XENE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (211.128).